About the Company
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EYPT News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Company granted stock options to purchase up to an aggregate of 77,000 shares of EyePoint Pharmaceuticals common stock to six new employees. The stock options were granted on March 15, 2024. The ...
What You Didn’t Know About EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) This Week
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) traded at $21.48 at close of the session on Friday, March 15, made a downward move of -1.20% on its previous day’s price. Looking at the stock we see that ...
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.8, a high estimate of $44.00, ...
5 Growth Stocks Under $50 for March 2024
These are 5 of the best-performing growth stocks for March 2024, that have shown above-average returns over the past year.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
March 7, 2024 EyePoint Pharmaceuticals, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the ...
EyePoint Pharmaceuticals Inc EYPT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR - - Initiation of first Phase 3 clinical trial (LUGANO) of EYP-1 ...
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript
At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Development Conference Call. There will be a ...
EyePoint Pharmaceuticals Inc EYPT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
EyePoint Pharmaceuticals, Inc. (EYPT)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
Operator: Thank you. One moment for our next question. Our next question comes from the line of Yi Chen from H.C. Wainwright. Your line is open. Yi Chen: Thank you for taking my question. Can you ...
Loading the latest forecasts...